Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
about
Radiotherapy and "new" drugs-new side effects?Functional outcomes after chemoradiotherapy of laryngeal and pharyngeal cancersHyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results.Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancerPhase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.Cetuximab: its unique place in head and neck cancer treatmentRecent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer.EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation.AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.
P2860
Q26861498-976B1FF2-5CA8-49E7-9812-10794E13D9A4Q26866157-82471CD4-9775-4396-BA16-E27C303FDD16Q30313175-2A5087B3-13BE-47CE-92AC-94B95995D1DBQ33410822-97DD1C4E-B436-4D4B-ABC5-BAF802F98614Q34385645-08C64BBE-80BA-4999-B804-D5C83FAEE98CQ34631723-05E428FA-29C7-40E8-9A96-C060B529BF94Q35611873-30E4B6C6-2A2C-4CF3-B444-0895566AB3E4Q36371601-7A88EA5C-5F0D-420F-AF2D-F556B8B026BDQ36880604-26F978A9-2402-4FD8-8D4A-63068C9625BEQ38191864-223F2319-A633-4150-B262-A194E80E9842Q39011609-904C0B6A-B9A0-499C-A622-384C07431268Q48240243-8B3063AA-7D46-4821-B523-D479FB67F340
P2860
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase II study evaluating the ...... rcinomas of the head and neck.
@ast
Phase II study evaluating the ...... rcinomas of the head and neck.
@en
type
label
Phase II study evaluating the ...... rcinomas of the head and neck.
@ast
Phase II study evaluating the ...... rcinomas of the head and neck.
@en
prefLabel
Phase II study evaluating the ...... rcinomas of the head and neck.
@ast
Phase II study evaluating the ...... rcinomas of the head and neck.
@en
P2093
P2860
P1476
Phase II study evaluating the ...... rcinomas of the head and neck.
@en
P2093
Ann Zimrin
Arti Parekh
Jeffrey Wolf
Kevin J Cullen
Mohan Suntharalingam
Olga Goloubeva
Robert Ord
Rodney Taylor
Scott Strome
Young Kwok
P2860
P304
P356
10.1016/J.IJROBP.2011.02.062
P407
P577
2011-05-19T00:00:00Z